Good question. I have followed the company DJknows is referring to for about 20 years. GNBT. They, or more specifically their public but not yet trading subsidiary, NuGenerex Immuno-Oncology has breast cancer data over more than a 10 year period showing their vaciine provides protection at least that long. They are working with Merck on a combo study with Keytruda. They lack funding so it is going quite slow.

They have a non RNA based covid vaccine in the works and the early data was excellent. They expect the same safety and long term immunity as the cancer data indicates. Why haven't you heard about it? The company has been completely silent for months. One, they are under review by the SEC due to Covid related claims made by the companies management. Secondly NGIO has an IPO pending so therefore a quiet period exists. It is an interesting company and there are many similarities between Generex and Cytodyn.

I have actually introduced Dr Pourhassan and the Generex CEO to each other via email, although I am not sure they got together. They could learn alot from each other.